×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Therapeutic: NAD+ Precursors (NMN/NR) for Parkinson's Disease
therapeutic
1,822 words
KG: NAD+
Contents
NAD+ Precursors (NMN/NR) for Parkinson's Disease
💊
Therapeutic Info
Name
NAD+
Key Genes/Proteins
AMPK
,
CD38
,
CX43
,
PARP1
,
SIRT1
Related Pathways
Cellular Processes
Linked Hypotheses
16 hypotheses
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor
Score: 0.53
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Senescence-Activated NAD+ Depletion Rescue
Score: 0.76
Smartphone-Detected Motor Variability Correction
Score: 0.74
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.91
Transcriptional Autophagy-Lysosome Coupling
Score: 0.88
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.79
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.78
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.77
Circadian Clock-Autophagy Synchronization
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
Senescent Cell Mitochondrial DNA Release
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
Senescence-Associated Myelin Lipid Remodeling
Score: 0.73
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.73
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.73
Proteostasis Enhancement via APOE Chaperone Targeting
Score: 0.72
HDAC3-Selective Inhibition for Clock Reset
Score: 0.71
Autophagosome Maturation Checkpoint Control
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.70
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.67
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.65
Show 25 more
Related Analyses (29)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · completed
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Show 24 more
Related Experiments (30)
NAD depletion effects on monocyte/macrophage differentiation
exploratory · proposed · Score: 0.90
Germfree mouse colonocyte energy metabolism analysis
validation · proposed · Score: 0.90
FK866 treatment in DSS-induced colitis mouse model
validation · proposed · Score: 0.90
FK866 in azoxymethane/DSS colitis-associated cancer model
validation · proposed · Score: 0.85
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Proposed experiment from debate on Epigenetic clocks and bio
falsification · proposed · Score: 0.40
Sirtuin Pathway Dysfunction Validation in Parkinson's Diseas
clinical · proposed · Score: 0.40
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Microglial Aging and Immune Memory in Neurodegeneration — Tr
validation · proposed · Score: 0.40
Sirtuin Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Peroxisomal Dysfunction Validation in Parkinson's Disease
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Show 25 more
See Also (5)
ATP P2X3 Receptor Neurons
cell · KG edge: causes
AMPK (AMP-Activated Protein Kinase)
entity · KG edge: activates
CD38 Molecule (CD38)
gene · KG edge: degrades
APP Gene Dosage Reduction Therapy for Down Syndrome
idea · KG edge: inhibits
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: inhibits
Knowledge Graph (12 edges)
NAD+
activates
SIRT1
AMPK
contributes_to
NAD+
NAD+
regulates
SIRT1
NAD+
modulates
SIRT1
CD38
depletes
NAD+
PARP
degrades
NAD+
SIRT
degrades
NAD+
NAD+
protects_against
BLOOD-BRAIN BARRIER DAMAGE
NAD+
associated_with
Cellular Processes
NAD+
modulates
inflammation
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)